MFG
NKTR icon

Magnus Financial Group’s Nektar Therapeutics NKTR Stock Holding History

Magnus Financial Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-654
Closed -$227K – 516
2020
Q2 		$227K Buy
+654
New +$204K 0.03% 515

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Magnus Financial Group's NKTR Position: Q3 2020 in Review

Magnus Financial Group sold out of Nektar Therapeutics (NKTR) in Q3 2020, closing a stake of 654 shares — an estimated $227K sold.

Magnus Financial Group first reported a position in NKTR in Q2 2020 and held it in 1 quarter. The position peaked at $227K in Q2 2020. 249 funds tracked by Wall St. Rank hold NKTR as of Q3 2020.

  • Magnus Financial Group reported no remaining Nektar Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Magnus Financial Group sold 654 Nektar Therapeutics shares in Q3 2020, an estimated $227K.
  • Magnus Financial Group first reported a position in Nektar Therapeutics in Q2 2020 and held it in 1 quarter.
  • Magnus Financial Group's Nektar Therapeutics position peaked at $227K in Q2 2020.
  • 249 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2020.

Based on Magnus Financial Group's 13F filing for Q3 2020, filed 5 Nov 2020.